Does the media refer more to BCAX or DNTH?

In the previous week, Dianthus Therapeutics had 6 more articles in the media than Bicara Therapeutics. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 1 mentions for Bicara Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.56 beat Bicara Therapeutics' score of 0.51 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, COGT or BCAX?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.16 N/A Bicara Therapeutics N/A N/A -$137.95M -$3.10 N/A

Is COGT or BCAX more profitable?

Bicara Therapeutics' return on equity of -41.49% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -84.47% -47.72% Bicara Therapeutics N/A -41.49% -38.59%

Does the media favor COGT or BCAX?

In the previous week, Cogent Biosciences had 7 more articles in the media than Bicara Therapeutics. MarketBeat recorded 8 mentions for Cogent Biosciences and 1 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.51 beat Cogent Biosciences' score of 0.24 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ERAS or BCAX?

Erasca is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.95 N/A Bicara Therapeutics N/A N/A -$137.95M -$3.10 N/A

Is ERAS or BCAX more profitable?

Erasca's return on equity of -38.43% beat Bicara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -38.43% -32.05% Bicara Therapeutics N/A -41.49% -38.59%

Does the media prefer ERAS or BCAX?

In the previous week, Erasca had 4 more articles in the media than Bicara Therapeutics. MarketBeat recorded 5 mentions for Erasca and 1 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.51 beat Erasca's score of 0.14 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Bicara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BCAX or XENE more profitable?

Bicara Therapeutics' return on equity of -41.49% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Bicara Therapeutics N/A -41.49% -38.59% Xenon Pharmaceuticals N/A -43.98% -41.72%

Does the media favor BCAX or XENE?

In the previous week, Xenon Pharmaceuticals had 26 more articles in the media than Bicara Therapeutics. MarketBeat recorded 27 mentions for Xenon Pharmaceuticals and 1 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.51 beat Xenon Pharmaceuticals' score of -0.31 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 7 Negative mention(s) 3 Very Negative mention(s) Neutral

Bicara Therapeutics (BCAX) Competitors

$22.64 +0.05 (+0.22%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$22.65 +0.01 (+0.04%)

As of 09/18/2026 07:30 PM Eastern

Compare

BCAX vs. KNSA, DNTH, COGT, ERAS, and XENE

Should you buy Bicara Therapeutics stock or one of its competitors? Bicara Therapeutics's main competitors and comparable companies include Kiniksa Pharmaceuticals International (KNSA), Dianthus Therapeutics (DNTH), Cogent Biosciences (COGT), Erasca (ERAS), and Xenon Pharmaceuticals (XENE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Bicara Therapeutics compare to Kiniksa Pharmaceuticals International?

Bicara Therapeutics (NASDAQ:BCAX) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Bicara Therapeutics currently has a consensus price target of $32.64, suggesting a potential upside of 44.15%. Kiniksa Pharmaceuticals International has a consensus price target of $87.38, suggesting a potential upside of 13.23%. Given Bicara Therapeutics' higher probable upside, equities research analysts plainly believe Bicara Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 13.8% of Bicara Therapeutics shares are held by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A
Kiniksa Pharmaceuticals International	$677.56M	8.89	$59.01M	$0.97	79.56

In the previous week, Bicara Therapeutics had 1 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 1 mentions for Bicara Therapeutics and 0 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.06 beat Bicara Therapeutics' score of 0.51 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Overall Sentiment
Bicara Therapeutics	Positive
Kiniksa Pharmaceuticals International	Positive

Bicara Therapeutics has a beta of -0.82, meaning that its share price is 182% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Bicara Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-41.49%	-38.59%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Summary

Kiniksa Pharmaceuticals International beats Bicara Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Bicara Therapeutics compare to Dianthus Therapeutics?

Bicara Therapeutics (NASDAQ:BCAX) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Bicara Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -10,096.95%. Dianthus Therapeutics' return on equity of -22.53% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-41.49%	-38.59%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Bicara Therapeutics has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A
Dianthus Therapeutics	$2.04M	2,594.41	-$162.34M	-$4.15	N/A

Bicara Therapeutics has a beta of -0.82, meaning that its stock price is 182% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

Bicara Therapeutics presently has a consensus price target of $32.64, suggesting a potential upside of 44.15%. Dianthus Therapeutics has a consensus price target of $129.83, suggesting a potential upside of 34.11%. Given Bicara Therapeutics' higher probable upside, equities analysts plainly believe Bicara Therapeutics is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 13.8% of Bicara Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Dianthus Therapeutics had 6 more articles in the media than Bicara Therapeutics. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 1 mentions for Bicara Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.56 beat Bicara Therapeutics' score of 0.51 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dianthus Therapeutics beats Bicara Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Bicara Therapeutics compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Bicara Therapeutics (NASDAQ:BCAX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Cogent Biosciences is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

Cogent Biosciences has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.82, meaning that its share price is 182% less volatile than the broader market.

Bicara Therapeutics' return on equity of -41.49% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
Bicara Therapeutics	N/A	-41.49%	-38.59%

Cogent Biosciences currently has a consensus price target of $51.56, indicating a potential upside of 63.67%. Bicara Therapeutics has a consensus price target of $32.64, indicating a potential upside of 44.15%. Given Cogent Biosciences' higher possible upside, equities research analysts plainly believe Cogent Biosciences is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

In the previous week, Cogent Biosciences had 7 more articles in the media than Bicara Therapeutics. MarketBeat recorded 8 mentions for Cogent Biosciences and 1 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.51 beat Cogent Biosciences' score of 0.24 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bicara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bicara Therapeutics beats Cogent Biosciences on 7 of the 11 factors compared between the two stocks.

How does Bicara Therapeutics compare to Erasca?

Erasca (NASDAQ:ERAS) and Bicara Therapeutics (NASDAQ:BCAX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

In the previous week, Erasca had 4 more articles in the media than Bicara Therapeutics. MarketBeat recorded 5 mentions for Erasca and 1 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.51 beat Erasca's score of 0.14 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Bicara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

67.8% of Erasca shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 13.8% of Bicara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Erasca presently has a consensus target price of $22.09, indicating a potential upside of 49.57%. Bicara Therapeutics has a consensus target price of $32.64, indicating a potential upside of 44.15%. Given Erasca's higher probable upside, analysts clearly believe Erasca is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

Erasca's return on equity of -38.43% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-38.43%	-32.05%
Bicara Therapeutics	N/A	-41.49%	-38.59%

Erasca has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.82, suggesting that its share price is 182% less volatile than the broader market.

Summary

Erasca beats Bicara Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Bicara Therapeutics compare to Xenon Pharmaceuticals?

Bicara Therapeutics (NASDAQ:BCAX) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 13.8% of Bicara Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bicara Therapeutics currently has a consensus target price of $32.64, indicating a potential upside of 44.15%. Xenon Pharmaceuticals has a consensus target price of $70.93, indicating a potential upside of 78.45%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Bicara Therapeutics' return on equity of -41.49% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-41.49%	-38.59%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

Bicara Therapeutics has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A
Xenon Pharmaceuticals	$7.50M	512.35	-$345.91M	-$4.74	N/A

In the previous week, Xenon Pharmaceuticals had 26 more articles in the media than Bicara Therapeutics. MarketBeat recorded 27 mentions for Xenon Pharmaceuticals and 1 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.51 beat Xenon Pharmaceuticals' score of -0.31 indicating that Bicara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	7 Negative mention(s)	3 Very Negative mention(s)	Neutral

Bicara Therapeutics has a beta of -0.82, suggesting that its share price is 182% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Summary

Xenon Pharmaceuticals beats Bicara Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Bicara Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAX vs. The Competition

Export

Metric	Bicara Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.50B	$3.92B	$7.24B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	N/A	14.30	275.79	25.40
Price / Sales	N/A	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	3.09	15.45	10.46	6.33
Net Income	-$137.95M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-0.75%	-1.21%	0.59%	1.12%
1 Month Performance	-12.45%	-4.42%	-2.01%	-2.67%
1 Year Performance	116.86%	37.81%	18.09%	6.01%

Bicara Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAX Bicara Therapeutics	2.1719 of 5 stars	$22.64 +0.2%	$32.64 +44.2%	+104.7%	$1.50B	N/A	N/A	103
KNSA Kiniksa Pharmaceuticals International	3.9759 of 5 stars	$75.15 -1.9%	$87.38 +16.3%	+114.8%	$5.98B	$677.56M	77.47	366	Positive News
DNTH Dianthus Therapeutics	2.305 of 5 stars	$104.77 -2.7%	$129.83 +23.9%	+149.1%	$5.89B	$2.04M	N/A	92	Insider Trade
COGT Cogent Biosciences	2.178 of 5 stars	$32.74 -2.0%	$51.56 +57.5%	+147.6%	$5.80B	N/A	N/A	258	Analyst Forecast
ERAS Erasca	2.1494 of 5 stars	$16.25 +0.6%	$22.09 +35.9%	+689.8%	$5.65B	N/A	N/A	103

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAX) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicara Therapeutics (BCAX) Competitors

BCAX vs. KNSA, DNTH, COGT, ERAS, and XENE

How does Bicara Therapeutics compare to Kiniksa Pharmaceuticals International?

Summary

How does Bicara Therapeutics compare to Dianthus Therapeutics?

Summary

How does Bicara Therapeutics compare to Cogent Biosciences?

Summary

How does Bicara Therapeutics compare to Erasca?

Summary

How does Bicara Therapeutics compare to Xenon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX vs. The Competition

Bicara Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicara Therapeutics (BCAX) Competitors

BCAX vs. KNSA, DNTH, COGT, ERAS, and XENE

How does Bicara Therapeutics compare to Kiniksa Pharmaceuticals International?

Do analysts rate BCAX or KNSA?

Do insiders & institutionals have more ownership in BCAX or KNSA?

Which has better earnings & valuation, BCAX or KNSA?

Does the media prefer BCAX or KNSA?

Which has more volatility & risk, BCAX or KNSA?

Is BCAX or KNSA more profitable?

Summary

How does Bicara Therapeutics compare to Dianthus Therapeutics?

Is BCAX or DNTH more profitable?

Which has stronger valuation & earnings, BCAX or DNTH?

Which has more risk and volatility, BCAX or DNTH?

Do analysts prefer BCAX or DNTH?

Do institutionals & insiders hold more shares of BCAX or DNTH?

Does the media refer more to BCAX or DNTH?

Summary

How does Bicara Therapeutics compare to Cogent Biosciences?

Which has higher earnings & valuation, COGT or BCAX?

Which has more volatility and risk, COGT or BCAX?

Is COGT or BCAX more profitable?

Do analysts prefer COGT or BCAX?

Does the media favor COGT or BCAX?

Summary

How does Bicara Therapeutics compare to Erasca?

Does the media prefer ERAS or BCAX?

Which has stronger earnings and valuation, ERAS or BCAX?

Do insiders & institutionals hold more shares of ERAS or BCAX?

Do analysts recommend ERAS or BCAX?

Is ERAS or BCAX more profitable?

Which has more risk & volatility, ERAS or BCAX?

Summary

How does Bicara Therapeutics compare to Xenon Pharmaceuticals?

Do insiders and institutionals believe in BCAX or XENE?

Do analysts rate BCAX or XENE?

Is BCAX or XENE more profitable?

Which has preferable valuation and earnings, BCAX or XENE?

Does the media favor BCAX or XENE?

Which has more risk & volatility, BCAX or XENE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX vs. The Competition

Bicara Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools